TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11063393
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) mouthwash, performed twice daily for 3 weeks
Study: 11063393
Drug: Amine fluoride/stannous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amine fluoride/stannous fluoride (AmF/SnF2) mouthwash, performed twice daily for 3 weeks
Study: 8832997
Drug: Zolpidem 5
Normalized name: zolpidem 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 5 mg, 10 mg, or 15 mg at bedtime
Study: 25134378
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum procalcitonin (> 0.5 ng/mL)
Study: 25134378
Drug: Procalcitonin >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin > 1.0 ng/mL
Study: 21068427
Drug: Bihemispheric transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bihemispheric transcranial direct current stimulation (tDCS) with simultaneous physical/occupational therapy
Study: 21068427
Drug: Sham stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulation with simultaneous physical/occupational therapy
Study: 17694946
Drug: Cemented, implant-retained
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented, implant-retained fixed superstructures in periodontally healthy patients
Study: 9466021
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion preceded by normal saline (group P, n = 12)
Study: 7629003
Drug: Uni-Dur (q24h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uni-Dur (q24h extended-release theophylline)
Study: 7629003
Drug: Theo-Dur (q12h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (q12h extended-release theophylline)
Study: 2380943
Drug: Prescription information
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription information leaflets
Study: 2380943
Drug: No prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prescription information leaflets (Control)
Study: 366143
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg levamisole once weekly
Study: 366143
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg levamisole on 3 or 7 consecutive days
Study: 23864786
Drug: Amitriptyline (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (12.5 mg tid)
Study: 19176454
Drug: Sequential chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemotherapy followed by radiotherapy (70 Gy total) after two cycles of cisplatin and 5‐fluorouracil, with a 50% or more reduction in primary tumor size.
Study: 19176454
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy and radiotherapy (60 Gy total) with four cycles of cisplatin and 5‐fluorouracil alternated with radiotherapy (20 Gy during the three 2‐week intervals).
Study: 17245803
Drug: Anthrax vaccine
Normalized name: ANTHRAX VACCINE
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthrax vaccine
Study: 15792325
Drug: Iowa Case
Normalized name: influenza B virus B/Iowa/06/2017 antigen
DrugBank: Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated) (DB15508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iowa Case Management Project (ICMP) for Rural Drug Abuse
Study: 12368673
Drug: GH plus
Normalized name: Pediacare Cough Plus Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH plus propranolol therapy
Study: 12368673
Drug: Combination GH
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination GH plus propranolol therapy
Study: 20726913
Drug: Intracanal medication
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracanal medication with calcium hydroxide [Ca(OH)(2)] for 1 week (n=35)
Study: 15751152
Drug: Pegvisomant (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (10 mg to 20 mg/day subcutaneously)
Study: 8777660
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of 25% sucrose solution
Study: 1920344
Drug: Nicardipine 60
Normalized name: niCARdipine 60 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 60 or 90 mg/day
Study: 1920344
Drug: Propranolol 90-240
Normalized name: propranolol hydrochloride 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 90-240 mg/day
Study: 6136290
Drug: Diazepam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.15 mg kg‐1)
Study: 26868210
Drug: Anti-asthma drug
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-asthma drug prescription
Study: 26868210
Drug: Anti-asthmatic medication
Normalized name: pramoxine hydrochloride Medicated Pad [Scalpicin Anti-Itch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-asthmatic medication use in Viborg vascular trial
Study: 12388959
Drug: Acetaminophen 650
Normalized name: acetaminophen 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 650 mg every 4 hours
Study: 23576267
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment twice weekly for 4 weeks
Study: 7770313
Drug: Desipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine (25 mg four times daily)
Study: 7770313
Drug: Clonidine (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.05 mg four times daily)
Study: 8752186
Drug: Lovastatin 40
Normalized name: lovastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 40 mg once daily
Study: 8628597
Drug: Lovastatin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (all doses)
Study: 22872323
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml simple olive oil (OO)
Study: 22872323
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml EGCG-supplemented olive oil (OO)
Study: 19926959
Drug: Enhanced labor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced labor ward-based services for PMTCT (opt-in HIV testing and NVP administration)
Study: 10235351
Drug: Prophylactic tropisetron
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic tropisetron 5 mg orally before anesthesia
Study: 27451818
Drug: DOTS Category
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS Category I treatment plus prednisolone 1mg/kg for first 4 weeks, then tapered down
Study: 27451818
Drug: DOTS Category
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS Category I treatment plus placebo
Study: 27451818
Drug: DOTS Category
Normalized name: D3 Dots
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTS Category I treatment plus prednisolone
Study: 24213955
Drug: 3 hours
Normalized name: nitroglycerin 0.3 MG/HR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 hours of rehabilitation treatment including aerobic exercise for 28 days (Group 1)
Study: 24213955
Drug: Not therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not therapy (control; Group 2)
Study: 20090328
Drug: Resin infiltration
Normalized name: Benzoin resin
DrugBank: Benzoin resin (DB11222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resin infiltration (etched for 5 s with 37% H(3)PO(4) and infiltrated twice for 60 s)
Study: 20090328
Drug: Untreated control
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated control (no treatment applied)
Study: 16002181
Drug: Sustained-release chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release chlorhexidine dressing
Study: 11974977
Drug: Pericranial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericranial injection of 10 x 20 MU DYSPORT
Study: 10759934
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of isotonic saline (placebo)
Study: 6971940
Drug: Anti-inflammatory analgesics
Normalized name: NON-STEROIDAL ANTI-INFLAMMATORY ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory analgesics
Study: 26964827
Drug: Nebulized magnesium
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized magnesium sulfate (3 ml of 260 mmol/L solution every 20 to 60 minutes)
Study: 20564607
Drug: Alverine citrate
Normalized name: alverine citrate
DrugBank: Alverine (DB01616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alverine citrate 120 mg capsule
Study: 17013645
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (1 mg intravenously every 3 months for a total of four doses)
Study: 16119667
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of physical state after treatment
Study: 11124916
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin A supplementation (5000 IU/day)
Study: 9701528
Drug: Trimebutine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine (50 mg intravenous injection)
Study: 8029677
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous cholangiography
Study: 8029677
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative intravenous cholangiography
Study: 30875348
Drug: Lapatinib 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1000 mg daily with eribulin 1.23 mg/m (split-dose arm) days 1+8 every 21 days
Study: 30875348
Drug: Eribulin 1.76
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.76 mg/m (3-weekly arm) day 1 every 21 days
Study: 30695420
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment of Western medicine (WM) and retention enema of Chinese medicine (CM)
Study: 21624541
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (6 g/day for a mean of 40 ± 12 days)
Study: 16682588
Drug: Simvastatin (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (daily administration for 7 days)
Study: 16682588
Drug: Simvastatin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (90 minutes after administration)
Study: 16682588
Drug: Simvastatin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (90 minutes and 7 days after administration)
Study: 11406520
Drug: D2E7 (anti-TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2E7 (anti-TNF monoclonal antibody)
Study: 7810814
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing two antibiotics
Study: 7810814
Drug: Ointment containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment containing one antibiotic plus hydrocortisone
Study: 26571890
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of auricular point sticking and Xiaopijian
Study: 24260195
Drug: FMP2.1/AS02A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMP2.1/AS02A vaccine
Study: 1689740
Drug: Finasteride (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (doses of 0.2-80 mg)
Study: 30400934
Drug: 3-month malaria
Normalized name: PLASMODIUM MALARIAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-month malaria chemoprevention (PMC) with monthly 3-day treatment courses of dihydroartemisinin-piperaquine at 2, 6, and 10 weeks after discharge
Study: 30400934
Drug: Standard in-hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard in-hospital care plus a single 3-day treatment course with artemether-lumefantrine at discharge
Study: 24799520
Drug: Initial antiepileptic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antiepileptic treatment
Study: 24799520
Drug: EEG characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: EEG characteristics prior to treatment
Study: 22381025
Drug: Encapsulated supplement
Normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Encapsulated supplement of fruit and vegetable juice concentrate (FVJC) for 6 months
Study: 18046109
Drug: Irbesartan/HCTZ 300/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/HCTZ 300/25 mg once daily for 7 to 8 weeks
Study: 10549460
Drug: Propofol infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol infusion, 1 mg kg‐1 min‐1 intravenous for 2 min, followed by propofol infusion, 200 micrograms kg‐1 min‐1
Study: 10549460
Drug: Fentanyl bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl bolus, 1 microgram kg‐1 intravenous + propofol infusion as in Group P
Study: 10549460
Drug: Fentanyl bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl bolus, 2 micrograms kg‐1 intravenous + propofol infusion as in Group P
Study: 10549460
Drug: Fentanyl bolus,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl bolus, 3 micrograms kg‐1 intravenous + propofol infusion as in Group P
Study: 153862
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide treatment for 4 weeks
Study: 153862
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide treatment for 1 week
Study: 30987164
Drug: Hydromorphone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone treatment
Study: 15370684
Drug: 4% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% ethanol solution
Study: 15370684
Drug: 10% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% ethanol solution
Study: 15370684
Drug: 40% ethanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40% ethanol solution
Study: 15370684
Drug: Water (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (500 mL)
Study: 11867933
Drug: Etidronate (EHDP)
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate (EHDP) therapy
Study: 10221416
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg once daily (q.i.d.)
Study: 10221416
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg twice daily (b.i.d.)
Study: 8657840
Drug: lorazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam (2 mg PO)
Study: 8657840
Drug: scopolamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: scopolamine (0.5 mg IV)
Study: 8657840
Drug: glycopyrrolate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate (0.2 mg IV)
Study: 6772045
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition preoperatively (group 1)
Study: 6772045
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition postoperatively (group 2)
Study: 31538372
Drug: Osmotic‐Release Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic‐Release Oral System Methylphenidate (OROS‐MPH)
Study: 30387461
Drug: Triamcinolone ointment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone ointment
Study: 30387461
Drug: Water-based gel
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based gel (Control)
Study: 12324291
Drug: L-796568 (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-796568 (375 mg/d)
Study: 8151001
Drug: Adinazolam mesylate
Normalized name: mesylate
DrugBank: Adinazolam (DB00546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adinazolam mesylate sustained release tablets, dosages titrated from 30 mg/day up to a maximum of 120 mg/day.
Study: 8751014
Drug: Ketoprofen 150
Normalized name: ketoprofen 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 150 mg
Study: 29576114
Drug: Goal-directed haemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed haemodynamic therapy (GDHT) using oesophageal Doppler monitor, aimed to maintain stroke volume, mean arterial pressure >70 mm Hg, and cardiac index ≥2.5 litres min‐1 m‐2
Study: 29576114
Drug: Goal-directed haemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed haemodynamic therapy (GDHT)
Study: 25588353
Drug: Levodopa-carbidopa intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel (LCIG) in LCIG-naïve patients (N = 29)
Study: 25588353
Drug: Levodopa-carbidopa intestinal
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa-carbidopa intestinal gel (LCIG) in continuing-LCIG patients (N = 33)
Study: 20185731
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin (CSII)
Study: 18232724
Drug: Levetiracetam (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (maximum dose of 3000 mg/day)
Study: 10762579
Drug: Inhaled zanamivir
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled zanamivir (10 mg twice daily for 5 days)
Study: 8103820
Drug: Monoclonal-antibody-purified FVIII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal-antibody-purified FVIII concentrates
Study: 27412789
Drug: D2-receptor antagonist
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2-receptor antagonist haloperidol
Study: 25941810
Drug: 2 calcium-fortified
Normalized name: calcium(2+) chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 calcium-fortified cereal bars daily (total of 400 mg calcium/day)
Study: 25941810
Drug: 2 calcium-fortified
Normalized name: calcium(2+) chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 calcium-fortified cereal bars daily
Study: 17559359
Drug: Lansoprazole, bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, bismuth subcitrate, metronidazole, and amoxicillin (LBMA)
Study: 17559359
Drug: Lansoprazole, bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, bismuth subcitrate, tetracycline, and amoxicillin (LBTA)
Study: 17128840
Drug: 5% dexpanthenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% dexpanthenol and zinc oxide ointment
Study: 14618470
Drug: 20-mg oestradiol
Normalized name: estradiol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg oestradiol implants, replaced every 4 months
Study: 11069229
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) daily for 3 months, followed by IFN 3 times weekly (TIW) for 12 months (group A)
Study: 11069229
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) 3 times weekly (TIW) for 18 months (group B)
Study: 1439406
Drug: Test compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test compound
Study: 3969937
Drug: Zinc intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc intake of 18.5 mg/day for two consecutive weeks
Study: 3969937
Drug: Zinc intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc intake of 3.5 mg/day above the RDA for men
Study: 31450870
Drug: Endometrial scratching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial scratching with long agonist protocol
Study: 31450870
Drug: Endometrial scratching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrial scratching with antagonist protocol
Study: 31450870
Drug: Stimulation with
Normalized name: INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation with long agonist protocol
Study: 31450870
Drug: Stimulation with
Normalized name: INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation with antagonist protocol
Study: 29384859
Drug: Comprehensive periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive periodontal treatment
Study: 26519996
Drug: Higher beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher beta-blocker dose
Study: 10325501
Drug: 4-HPR (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-HPR (two 100-mg capsules daily for 3 weeks)
Study: 10325501
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules daily for 3 weeks)
Study: 8519723
Drug: Intravenous phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phentolamine infusion (i.v.P) at 35 mg
Study: 8519723
Drug: Intravenous phentolamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phentolamine infusion (i.v.P) at higher doses (50 mg or 75 mg)
Study: 6320943
Drug: Low-dose corticotrophin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose corticotrophin
Study: 20522594
Drug: TUDCA (1,750
Approvals — FDA: no, EMA: no, PMDA: no
Description: TUDCA (1,750 mg/day)
Study: 15642073
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR 1000 mg once daily
Study: 15642073
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR 500 mg once daily
Study: 15642073
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR 1500 mg once daily
Study: 15642073
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR 1000 mg twice daily
Study: 29227571
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XR